Headquartered in North Dakota but with research facilities in Sunnyvale, CA .,, Altravax, Inc., a biopharmaceutical company, uses its Protein and Immunogen Optimization Systems to create and improve protein function to prevent and treat disease. Product pipeline has included a tetravalent dengue vaccine; improved preventative vaccines for influenza and HIV-1; vaccines for thermostable rabies, dengue tetravalent, Hepatitis B virus, and seasonal and potential pandemic influenza viruses. Having a robust pipeline of candidates at various stages of development, including a therapeutic vaccine against chronic hepatitis B infection and a preventive vaccine against all four dengue virus, the firm's proprietary Immunogen Optimization System⢠(IOS) offers opportunities to create novel vaccines or improve currently available alternatives to fill unmet medical needs. The Company has
